Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Terrosa 20 micrograms/80 microliters solution for injection in pre-filled pen, Acido Alendronico Aurobindo 70 mg compresse
Gedeon Richter Australia Pty Ltd
Prevention of new morphometric vertebral fractures and/or worsening of previous vertebral fractures.
1 trial -
The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
AstraZeneca AB
Chronic Obstructive Pulmonary Disease
1 trial -
Tirofiban hydrochloride sodium chloride injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Branch Atheromatous Disease
1 trial -
Tislelizumab + cisplatin + paclitaxel
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Tofacitinib and Acitretin Capsules.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Cutaneous Amyloidosis
1 trial -
Topiramate
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Alcohol Dependence
1 trial -
Toujeo
Almirall, S.A.
Diabetes Mellitus, Type 2
1 trial -
Treatment group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Triple combination therapy group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Type 2 Diabetes Mellitus
1 trial -
VYDURA 75 mg oral lyophilisate, Placebo for Rimegepant 75 mg
Pfizer Australia Pty Ltd
Migraine attacks with or without aura
1 trial -
Vedolizumab Placebo
Takeda
Pouchitis
1 trial -
Voltaren SPORT, 11,6 mg/g, ΕΌel, Voltaren MAX, 23,2 mg/g, ΕΌel
HALEON AUSTRALIA PTY LTD
Mild/non-serious osteoarthritis (OA) of the knee.
1 trial -
Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
NovoThirteen
Obesity
1 trial -
Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen
Lacuna Pharma Pty Ltd
Adipositas
1 trial -
a control group
The First People's Hospital of Lianyungang
Disorder of Stomach Function and Feeding Problems in Newborn
1 trial -
allopurinol
United Therapeutics Europe Ltd
Gout
1 trial -
budesonide/formoterol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cough Variant Asthma
1 trial -
conventional dose epinephrine
Hospital Authority, Hong Kong
Croup
1 trial -
counseling
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine-Related Disorders
1 trial -
counseling
BRIGHT MINDS BIOSCIENCES INC.
Substance-Related Disorders
1 trial -
first-line scheme+compound kushen injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Colorectal Carcinoma
1 trial -
fluocinolone acetonide 190 micrograms
ANI PHARMACEUTICALS INC
Non-infectious Uveitis Affecting the Posterior Segment of the Eye
1 trial -
ginkgolide
The First People's Hospital of Lianyungang
Intravenous Alteplase Thrombolysis
1 trial -
hylenex-facilitated subcutaneous Lactated Ringer's infusion
HALOZYME THERAPEUTICS, INC.
Dehydration
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources